© 2005 The Japanese Biochemical Society
Regular Paper |
The Essential Role of Histone H3 Lys9 Di-Methylation and MeCP2 Binding in MGMT Silencing with Poor DNA Methylation of the Promoter CpG Island
1 Division of Molecular Biology and Genetics, Department of Biomolecular Sciences, Faculty of Medicine, Saga University, Saga 849-8501; 2 Department of Biochemistry II, Graduate School of Medicine, Nagoya University, Nagoya 466-8550; 3 Hokkaido Institute of Public Health, Sapporo 060-0819; and 4 Tanaka Hospital, Saga 849-0862
* To whom correspondence should be addressed. Phone: +81-952-34-2264, Fax: +81-952-34-2067, E-mail: soejimah{at}post.saga-med.ac.jp
ABSTRACT
Silencing of the O 6-methylguanine-DNA methyltransferase (MGMT) gene, a key to DNA repair, is involved in carcinogenesis. Recent studies have focused on DNA hypermethylation of the promoter CpG island. However, cases showing silencing with DNA hypomethylation certainly exist, and the mechanism involved is not elucidated. To clarify this mechanism, we examined the dynamics of DNA methylation, histone acetylation, histone methylation, and binding of methyl-CpG binding proteins at the MGMT promoter region using four MGMT negative cell lines with various extents of DNA methylation. Histone H3K9 di-methylation (H3me2K9), not tri-methylation, and MeCP2 binding were commonly seen in all MGMT negative cell lines regardless of DNA methylation status. 5Aza-dC, but not TSA, restored gene expression, accompanied by a decrease in H3me2K9 and MeCP2 binding. In SaOS2 cells with the most hypomethylated CpG island, 5Aza-dC decreased H3me2K9 and MeCP2 binding with no effect on DNA methylation or histone acetylation. H3me2K9 and DNA methylation were restricted to in and around the island, indicating that epigenetic modification at the promoter CpG island is critical. We conclude that H3me2K9 and MeCP2 binding are common and more essential for MGMT silencing than DNA hypermethylation or histone deacetylation. The epigenetic mechanism leading to silent heterochromatin at the promoter CpG island may be the same in different types of cancer irrespective of the extent of DNA methylation.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S Uccella, R Cerutti, C Placidi, S Marchet, I Carnevali, B Bernasconi, I Proserpio, G Pinotti, M G Tibiletti, D Furlan, et al. MGMT methylation in diffuse large B-cell lymphoma: validation of quantitative methylation-specific PCR and comparison with MGMT protein expression J. Clin. Pathol., August 1, 2009; 62(8): 715 - 723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Everhard, J. Tost, H. El Abdalaoui, E. Criniere, F. Busato, Y. Marie, I. G. Gut, M. Sanson, K. Mokhtari, F. Laigle-Donadey, et al. Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas Neuro Oncology, August 1, 2009; 11(4): 348 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.-C. Ma, C.-C. Kuo, J.-F. Liu, L.-T. Chen, and J.-Y. Chang Transcriptional Repression of O6-Methylguanine DNA Methyltransferase Gene Rendering Cells Hypersensitive to N,N'-Bis(2-chloroethyl)-N-nitrosurea in Camptothecin-Resistant Cells Mol. Pharmacol., August 1, 2008; 74(2): 517 - 526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Hinshelwood, L. I. Huschtscha, J. Melki, C. Stirzaker, A. Abdipranoto, B. Vissel, T. Ravasi, C. A. Wells, D. A. Hume, R. R. Reddel, et al. Concordant Epigenetic Silencing of Transforming Growth Factor- Signaling Pathway Genes Occurs Early in Breast Carcinogenesis Cancer Res., December 15, 2007; 67(24): 11517 - 11527. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. C. Galvao and J. O. Thomas Structure-specific binding of MeCP2 to four-way junction DNA through its methyl CpG-binding domain Nucleic Acids Res., November 27, 2005; 33(20): 6603 - 6609. [Abstract] [Full Text] [PDF]
|
|